SAN FRANCISCO, CA / ACCESS Newswire / August 19, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS) who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period") to […]
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”, HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monoclonal antibody (mAb) tagitanlimabfor the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) have been published in Nature Medicine (Impact Factor: 58.7).
Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine®2 for Injection, 50 mg/vial and 100 mg/vial, of
NEW YORK, NY / ACCESS Newswire / August 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Otis Worldwide Corporation ("Otis Worldwide Corporation") (NYSE:OTIS) concerning possible violations of federal securities laws. On July 23, 2025, Otis reported its second quarter fiscal 2025 earnings, unveiling net sales for the quarter
NEW YORK, NY / ACCESS Newswire / August 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Bruker Corporation ("Bruker Corporation") (NASDAQ:BRKR) concerning possible violations of federal securities laws. On July 21, 2025, Bruker announced disappointing preliminary results for the second quarter, ended June 30, 2025. The Company disclosed
NEW YORK, NY / ACCESS Newswire / August 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Informatica Inc. ("Informatica Inc.") (NYSE:INFA) concerning possible violations of federal securities laws. On February 13, 2025, Informatica issued a press release announcing its fourth quarter 2024 financial results, missing revenue forecasts and
NEW YORK, NY / ACCESS Newswire / August 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of V.F. Corporation ("V.F. Corporation") (NYSE:VFC) concerning possible violations of federal securities laws. On May 21, 2025, VFC issued a press release announcing that the company’s fourth quarter fiscal 2025 results failed to
Global Central Lab Services Market to Reach USD 8.18 Billion by 2030 | MarketsandMarkets(TM) Asia Pacific to lead growth as pharmaceutical innovation and advanced analytics reshape clinical research GlobeNewswire August 19, 2025 Delray Beach, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) — The global Central Lab Services Market, valued at US$5.64 billion in 2024, stood at
NEW YORK, NY / ACCESS Newswire / August 19, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=162253&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or
NEW YORK, NY / ACCESS Newswire / August 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has